Aktivierte Prothrombinkomplexkonzentrate

K. Lechner

doi:10.1055/s-0038-1656573

Hämostaseologie, Table of Contents

Hamostaseologie 1982; 02(03): 110-115
DOI: 10.1055/s-0038-1656573

Originalarbeiten

Schattauer GmbH

Aktivierte Prothrombinkomplexkonzentrate

K. Lechner

¹Aus der I. Medizinischen Universitätsklinik Wien (Vorstand: Prof. Dr. Dr. h. c. E. Deutsch) Abteilung für Hämatologie und Blutgerinnung

› Author Affiliations

Abstract

Full Text

References

LITERATUR
1 Abildgaard C. F., Britton M., Harrison J. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors. J. Pediat. 1976; 88: 200.
2 Abildgaard C. F., Penner J., Watson-Williams E. Anti-inhibitor coagulant complex (autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978.
3 Aronson D. L., Bagley J. Preliminary characterisation of factor VIII bypassing coagulant. Ann. N. Y. Acad. Sci. 1981; 370: 291.
4 Aronstam A., Aston L., Wassef M., Hamad Z. New activated factor IX product in haemophilia. Lancet II 1980; 1294.
5 Austen D. E. G., Lechner K., Rizza C. R., Rhymes I. L. A comparison of the Bethesda and new Oxford methods of factor VIII antibody assay. Thromb. Haemostas. 1982; 47: 72.
6 Austen D. E., Rhymes I. L. A laboratory manual of blood coagulation. Blackwell Scientific; Oxford: 1975
7 Barrowcliffe T. W., Kemball-Cook G., Gray E. Factor VIII inhibitor bypassing activity: A suggested mechanism of action. Thromb. Res. 1981; 21: 181.
8 Bloom A. L. Factor VIII inhibitors revisited. Brit. J. Haemat. 1981; 49: 319.
9 Breen F. A., Tullís J. L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA 1969; 208: 1818.
10 Buchanan G., Kevy S. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: Clinical and laboratory studies. Pediatrics 1978; 62: 767.
11 Elsinger F. Laboratory tests of activated prothrombin complex preparations. In: Mariani (ed.): The state of the Art of Managing hemophilia with factor VIII inhibitor. Praeger; New York: 1982
12 Fekete L. F., Holst S. L., Peetom F., Deveber L. L. Auto-factor IX concentrate: a new therapeutic approach to treatment of haemophilia A patients with inhibitors. 14th Intern. Congress of Hematology; Brazil.: Abstr. No. 295 1972
13 Fukui H., Fujimura Y., Takamashi Y., Mikami S., Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophiliac patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb. Res. 1981; 22: 177.
14 Hanna W. T., Madigan R. R., Miles M. A., Lange R. D. Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors. Thromb. Haemost. 1981; 46: 638.
15 Hilgartner M. W., Aledort L. M., Knatterud G. L. Verbal report to the subcommittee on factor IX concentrates. 8th Intern. Congress of Thromb. and Haemost. Toronto; Canada, July: 1981
16 Hoots W. K., Snyder M. S., McMillan C. S. Effects of activated prothrombin complex concentrates (APCC) for craniospinal haemorrhage in classic haemophiliacs with factor VIII inhibitors. Ped. Res. 1980; 14: 535.
17 Hultin M. B. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028.
18 Kasper C. K. Thromboembolic complications. Thromb. Diath. Haemorr. 1975; 32: 492.
19 Kasper C. K., Aledort L. M., Counts R. B. et al.: A more uniform measurement of factor VIII inhibitors. Thromb. Diath. Haemorr. 1975; 34: 869.
20 Kasper C. K. Hemophilia Study Group: Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 1979; 54: 1358.
21 Kazama M., Abe T. Analysis of the corrective effect of activated prothrombin complexes. Haemostasis 1981; 10: 215.
22 Kingdon H. S., Hassell T. M. An animal model for evaluating the haemostatic effectiveness of factor VIII inhibitor bypassing materials. Clin. Res. 1980; 28: 769.
23 Kurczynski E. M., Penner J. A. Activated prothrombin concentrate for patients with factor VIII inhibitors. New Engl. J. Med. 1974; 291: 164.
24 Lechner K. Differences in the immune response in hemophiliacs with acquired inhibitors. Workshop on Inhibitor to factor VIII and IX, Wien 48 1976
25 Lechner K. Acquired inhibitors in nonhemophilic patients. (Review). Haemostatis 1974; 3: 65.
26 Lechner K., Korninger Ch. Structure ,characteristics and natural history of factor VIII- and IX-inhibitors in non-hemophiliacs. In: Seligsohn et al. (eds.): »Haemophilia«. Castle House Publ. Ltd.; 1981: 87.
27 Lechner K., Nowotny C., Krinninger B., Zegner M., Deutsch E. The effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII antibody level. Thromb. Haemost. 1978; 40: 478.
28 Lusher J. M., Shapiro S. S., Palascak J. E. et al.:Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. New Engl. J. Med. 303: 421 1980;
29 Mannucci P. M., Bader R., Ruggieri Z. M. Concentrates of clotting factor IX. Lancet I: 41 1976;
30 Mannucci P. M., Federici A., Vigano S., Cattaneo M. Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors. Thromb. Res. 1979; 15: 359.
31 Nowotny C., Lechner K., Niessner H., Thaler E. Effect in vivo administration of FEIBA on clotting tests. Dose-response relationship. Thromb. Haemost. 1979; 42: 199.
32 Parry D. H., Bloom A. K. Failure of factor VIII inhibitor bypassing activity to secure haemostasis in hemophilia patients with antibodies. J. Clin. Pathol. 1978; 31: 1102.
33 Penner J. A. Therapeutic approaches to inhibitors: vitamin K-dependent factor concentrates. In: U. Seligsohn et al. (eds.): »Haemophilia« Castle House Publ. Ltd.; 97 1981
34 Penner J. A., Abildgaard C. F. Ineffectiveness of certain commercial prothrombin complex concentrates in treatment of patients with inhibitors of factors VIII and IX. New Engl. J. Med. 1979; 300: 565.
35 Penner J. A., Kelly P. E. Management of patients with factor VIII or IX inhibitors. Semin Thromb. Hemostas. 1975; 1: 386.
36 Pollock A., Lewis M. J. Factor VIII inhibitor bypassing activity. Lancet II: 43 1976;
37 Rasche H., Bindewald H., Köhle W. et al. :Notfallbehandlung von Blutungskomplikationen bei Hemmkörper-Hämophihe mit aktivierten Prothrombinkomplexkon-zentraten. Dtsch. med. Wschr. 1977; 102: 319.
38 Seligsohn U., Kasper C. K., Osterud B., Rapaport S. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828.
39 Sjamsoedin L. J. M., Heijnen L., Mauser-Bunschoten E. P. et al. : The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: a double-blind clinical trial. New Engl. J. Med. 1981; 305: 717.
40 Sonoda T., Solomon A., Krauss St., Cruz P., Jones F. S., Levin J. Use of prothrombin complex concentrates in the treatment of a hemophilic patient with an inhibitor of factor VIII. Blood 1976; 47: 983.
41 Stenbjerg S., Jørgensen J. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII. Acta Med. Scand. 1978; 203: 471.
42 Stenbjerg S., Tauris P., Skottun T., Jorgensen J. Total dental extraction in a patient with F VIII inhibitor. Thromb. Res. 1980; 18: 889.
43 Sultan Y., Brouet J. C., Debre P. Treatment of inhibitor to factor VIII with activated prothrombin concentrate. New Engl. J. Med. 1974; 291: 1087.
44 Thomas W., Ionia McDonald D. Potency determination of anti-inhibitor coagulant complex - Autoplex. Haemostasis 1981; 10: 216.
45 Vermylen J., Schetz J., Semeraro N., Mertens F., Verstraete M. Evidence that activated prothrombin concentrates enhance platelet coagulant activity. Brit. J. Haematol. 1978; 38: 235.
46 Vigano S., Cattaneo M., Gervasoni W., Mannucci P. M. Increased fibrinopeptide A after prothrombin complex concentrates. Thromb. Haemost. 1980; 44: 72.